Patient-derived intestinal organoids and tumouroids supplemented with immune cells can be used to predict and study the on-target off-tumour toxicities of T-cell-engaging bispecific antibodies and to capture inter-patient variabilities in the responses to the antibodies.
- Marius F. Harter
- Timothy Recaldin
- Nikolche Gjorevski
